{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-066364","form_type":"8-K","ticker":"BJDX","cik":"0001704287","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2026-06-08T21:15:17+00:00","discovered_at":"2026-06-08T21:16:00.275576+00:00","generated_at":"2026-06-08T21:16:37.585199+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bluejay Diagnostics closes $8.5M private placement with warrants for up to $23.7M total","bullets":["Closed private placement of 3,655,917 common shares (or pre-funded warrants) plus Series G and H warrants at $2.325/unit, raising $8.5M gross.","Net proceeds of ~$7.7M after placement agent fees; cash runway extended into Q1 2027, beyond expected FDA submission.","If all warrants exercised for cash, additional $15.2M proceeds would extend cash runway well beyond FDA approval and first year of commercialization.","Company must file resale registration statement by June 17, 2026 for underlying shares; warrants have exercise price $2.075."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-066364","json":"https://secwatch.observer/filing/0001213900-26-066364.json","markdown":"https://secwatch.observer/filing/0001213900-26-066364.md","text":"https://secwatch.observer/filing/0001213900-26-066364.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026066364/0001213900-26-066364-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026066364/ea0293390-8k_bluejay.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:16:37.585199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"452e8d3c6cd495ec587692f0cad9d09c0efd8a2b","claim":"Bluejay Diagnostics, Inc. issued pre-funded warrants to purchase up to 3,655,917 shares; Series G warrants to purchase up to 3,655,917 shares; Series H warrants to purchase up to 3,655,917 shar of warrant to institutional accredited investors for $2.324 per Pre-Funded Warrant and accompanying Series G Warrant and Series H Warrant.","evidence_excerpt":"and (iii) Series H warrants (the “Series H Warrants”) to purchase up to 3,655,917 shares of common stock. The combined price of securities sold in the private placement was $2.324 per Pre-Funded Warrant and accompanying Series G Warrant and Series H Warrant. The Pre-Funded Warrants are immediately exercisable for shares of common stock at an exercise price","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026066364/0001213900-26-066364-index.htm","confidence":0.95,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"pre-funded warrants to purchase up to 3,655,917 shares; Series G warrants to purchase up to 3,655,917 shares; Series H warrants to purchase up to 3,655,917 shar"},{"label":"Purchaser","value":"institutional accredited investors"},{"label":"Consideration","value":"$2.324 per Pre-Funded Warrant and accompanying Series G Warrant and Series H Warrant"}],"fact_type":"equity_issuance"},{"claim_id":"5d5364a7624d595db94b01ae50461dd4ea1c0f8c","claim":"Bluejay Diagnostics, Inc. issued Placement Agent Warrants to purchase up to an aggregate of 255,915 shares of common stock of warrant to H.C. Wainwright & Co. for services as placement agent.","evidence_excerpt":"the Company issued to the placement agent (or its designees) warrants (\"Placement Agent Warrants\"","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026066364/0001213900-26-066364-index.htm","confidence":0.95,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"Placement Agent Warrants to purchase up to an aggregate of 255,915 shares of common stock"},{"label":"Purchaser","value":"H.C. Wainwright & Co."},{"label":"Consideration","value":"services as placement agent"}],"fact_type":"equity_issuance"},{"claim_id":"66eed205f48448110fd092f499678f27015c09f9","claim":"Bluejay Diagnostics, Inc. entered into registration rights agreement with certain institutional, accredited investors (effective 2026-06-02).","evidence_excerpt":"On June 2, 2026, Bluejay Diagnostics, Inc. (the “Company”), in connection with a private placement of the Company’s securities, entered into with certain institutional, accredited investors (i) a securities purchase agreement, and (ii) a registration rights agreement (the “private placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026066364/0001213900-26-066364-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional, accredited investors"},{"label":"Effective","value":"2026-06-02"}],"fact_type":"material_agreement"},{"claim_id":"af1010b0bfaa45d92476dc27c265130b88610b8f","claim":"Bluejay Diagnostics, Inc. entered into securities purchase agreement with certain institutional, accredited investors valued at approximately $7.7 million (effective 2026-06-02).","evidence_excerpt":"On June 2, 2026, Bluejay Diagnostics, Inc. (the “Company”), in connection with a private placement of the Company’s securities, entered into with certain institutional, accredited investors (i) a securities purchase agreement, and (ii) a registration rights agreement (the “private placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026066364/0001213900-26-066364-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional, accredited investors"},{"label":"Value","value":"approximately $7.7 million"},{"label":"Effective","value":"2026-06-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}